We read with interest the commentary on aspirin in primary prevention by Gitin et al.1 As ASPirin in Reducing Events in the Elderly (ASPREE) investigators, 1 of 3 key aspirin primary prevention trials referenced in this paper, we write to reiterate the unambiguous message from the ASPREE trial.2